Vivoryon Therapeutics N.V.

  • WKN: A2QJV6
  • ISIN: NL00150002Q7
  • Land: Deutschland

Nachricht vom 28.06.2021 | 18:00

Vivoryon Therapeutics N.V.: Ordinary General Meeting of Shareholders of Vivoryon Therapeutics N.V.

DGAP-News: Vivoryon Therapeutics N.V. / Key word(s): AGM/EGM
28.06.2021 / 18:00
The issuer is solely responsible for the content of this announcement.

 

Ordinary General Meeting of Shareholders of Vivoryon Therapeutics N.V.

 

HALLE (SAALE) / MUNICH, GERMANY, June 28, 2021 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon) a clinical-stage biotechnology company focused on developing innovative small molecule-based medicines today announced, that its shareholders approved all resolutions proposed by the Company's Board of Directors at the Company's Annual General Meeting which took place on Monday, June 28, 2021, as a virtual event, including the:

  • Advisory vote on the remuneration report.
  • Adoption of the 2020 annual accounts.
  • Release from liability of the company's executive directors.
  • Release from liability of the company's non-executive directors.
  • Adoption of the remuneration policy.
  • Re-appointment of Dr. Michael Schaeffer as executive member of the Board.
  • The Board nominated Dr. Michael Schaeffer for reappointment as executive member of the Board and regranted him the title of Chief Business Officer, effective October 1st, 2021.
  • Adoption of the long term incentive plan.
  • Amendments to the company's articles of association.
  • Re-appointment of KPMG Accountants N.V., The Netherlands,as external auditor for the financial year 2021.
  • Authorization to acquire own shares.


47.37 % of the voting shares were represented at the 2021 Vivoryon Therapeutics N.V. AGM.


All resolutions proposed by the Company's Board of Directors were approved at the meeting with a large majority. The voting results can be found on the Company's website:
www.vivoryon.com/investors-news/ordinary-general-meeting-of-shareholders-2021

 

Dr. Ulrich Dauer, Chief Executive Officer of Vivoryon Therapeutics N.V, said: "We would like to take this opportunity to thank all of our employees, advisors and consultants, as well as the members of the non-executive Board, partners and shareholders for their commitment, trust and support."
 

###


For more information, please contact:

Vivoryon Therapeutics N.V.
Investor Contact

Dr. Manuela Bader, Director IR & Communication
Tel: +49 (0)345 555 99 30
Email: IR@vivoryon.com


Media Contact
Trophic Communications

Gretchen Schweitzer / Valeria Fisher
Tel: +49 (0)172 861 8540 or +49 (0)175 8041816
Email: vivoryon@trophic.eu

About Vivoryon Therapeutics N.V.

Vivoryon is a clinical-stage biotechnology company focused on developing innovative small molecule-based medicines. Driven by our passion for ground-breaking science and innovation we strive to change the live of medically underserved patients suffering from severe diseases. We leverage our in-depth expertise in understanding post-translational modifications to develop medicines that modulate the activity and stability of proteins which are altered in disease settings before they cause irreversible damage. Beyond our lead program, varoglutamstat, which is in Phase2 clinical development to treat Alzheimer's disease, we have established a solid pipeline of orally available small molecule inhibitors for various indications including cancer, inflammatory diseases and fibrosis.

www.vivoryon.com

Forward Looking Statements

Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgment of Vivoryon Therapeutics N.V. as of the date of this press release. Such forward-looking statements are neither promises nor guarantees but are subject to a variety of risks and uncertainties, many of which are beyond our control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.



28.06.2021 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de



show this

Event im Fokus

Termine 2021

10. Juni 2021:Fachkonferenz Immobilien

14./15. Juli 2021: Fachkonferenzen Beteiligungsgesellschaften & Consumer/Leisure

13./14. Oktober 2021: Fachkonferenzen Finanzdienstleistungen/Technologie

10./11. November 2021: Fachkonferenzen Software/IT & Branchenmix

„Je nach aktueller Covid-19 Situation und den bestehenden Vorschriften für Versammlungen entscheidet sich ca. 5 Wochen vor dem Termin, in welcher Form die Konferenzen stattfinden.“

GBC-Fokusbox

Kaufen: Aspermont Limited hat Turnaround abgeschlossen

Aspermont Limited ist der weltweit führende Anbieter von Business-to-Business-Medien (B2B) für den Rohstoffsektor. Mit einem neuen Management hat das Unternehmen seit 2016 den erfolgreichen Turnaround von einem traditionellen Medienunternehmen zu einem digitalen B2B-XaaS-Geschäftsmodell umgesetzt. Das Unternehmen hat diesen Turnaround im GJ 2020 abgeschlossen, als es sein erstes positives EBITDA-Ergebnis verzeichnete. Auf der Grundlage unseres DCF-Modells haben wir ein Kursziel von 0,09 AUD (0,06 Euro) pro Aktie ermittelt und vergeben das Rating KAUFEN.

News im Fokus

Vonovia SE: Vonovia verkauft Berliner Wohnungsbestände aus dem Zukunfts- und Sozialpakt Wohnen

17. September 2021, 12:40

Aktueller Webcast

Stealth BioTherapeutics

Cantor Global Healthcare Conference Fireside Chat

30. September 2021

Aktuelle Research-Studie

CR Capital AG

Original-Research: CR Capital AG (von First Berlin Equity Research GmbH): Buy

17. September 2021